About Neurotensin receptor type 2
Neurotensin receptor type 2 (NTSR2) is a protein
from Homo sapiens identified by UniProt accession
O95665, 410 residues long.
MolForge cross-references it against 0 known binders and
64 disease associations.
Target properties
| Protein name | Neurotensin receptor type 2 |
| UniProt accession | O95665 |
| Gene | NTSR2 |
| Organism | Homo sapiens |
| Length | 410 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (1)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (64)
Diseases linked to this target (Open Targets).
- breast adenocarcinoma · score 0.25
- PHF-tau measurement · score 0.17
- head and neck squamous cell carcinoma · score 0.16
- body height · score 0.13
- endometriosis · score 0.12
- balding measurement · score 0.10
- creatinine measurement · score 0.10
- sex hormone-binding globulin measurement · score 0.10
- age at menarche · score 0.10
- testosterone measurement · score 0.10
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O95665-F1 | alphafold | PREDICTED | 78.87 | — |
Amino-acid sequence (410 residues)
METSSPRPPR PSSNPGLSLD ARLGVDTRLW AKVLFTALYA LIWALGAAGN ALSAHVVLKA RAGRAGRLRH HVLSLALAGL LLLLVGVPVE LYSFVWFHYP WVFGDLGCRG YYFVHELCAY ATVLSVAGLS AERCLAVCQP LRARSLLTPR RTRWLVALSW AASLGLALPM AVIMGQKHEL ETADGEPEPA SRVCTVLVSR TALQVFIQVN VLVSFVLPLA LTAFLNGVTV SHLLALCSQV PSTSTPGSST PSRLELLSEE GLLSFIVWKK TFIQGGQVSL VRHKDVRRIR SLQRSVQVLR AIVVMYVICW LPYHARRLMY CYVPDDAWTD PLYNFYHYFY MVTNTLFYVS SAVTPLLYNA VSSSFRKLFL EAVSSLCGEH HPMKRLPPKP QSPTLMDTAS GFGDPPETRT
Explore Neurotensin receptor type 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets